Safety of Ixekizumab Treatment for up to 5 Years in Adult Patients with Moderate-to-Severe Psoriasis: Results from Greater Than 17,000 Patient-Years of Exposure
Long-term safety data are critical for evaluating therapies for psoriasis. Ixekizumab has demonstrated efficacy and is well tolerated for the treatment of moderate-to-severe plaque psoriasis. We examined the safety and tolerability of up to 5 years of ixekizumab therapy in patients with psoriasis.
Integrated safety data were analyzed from 13 ixekizumab clinical studies. Rates of treatment-emergent adverse events (TEAEs), serious AEs (SAEs) and AEs of special interest were analyzed for the 12-week induction period in the combined pivotal studies, and for all pooled studies by year(s) of therapy and overall, reported as exposure-adjusted incidence rates (IRs) per 100 patient-years (p-y) and/or frequencies.
Total ixekizumab exposure was 17,003.4 p-y (N = 5898); 2749 patients had ≥ 4 years of exposure. When compared across years of exposure, rates for AEs remained largely stable or declined, including TEAEs leading to discontinuation (3.8/100 p-y in year 1, declining to 2.0/100 p-y in year 5); SAEs (range 6.2–7.0/100 p-y); serious infections (range 1.3–1.7/100 p-y); nonmelanoma skin cancer (ranging from 0.5/100 p-y in year 1 to 0.2/100 p-y in years 4–5); other malignancies (range 0.4–0.6/100 p-y); inflammatory bowel disease including ulcerative colitis and Crohn’s disease (IR 0.2/100 p-y); and major adverse cardiovascular events (MACE) (range 0.3–0.7/100 p-y). Candidiasis was reported in 327 patients (IR 1.9/100 p-y), with the majority identified as mucocutaneous. The rate of injection site reactions was 15.5/100 p-y during year 1 and 2.0–2.3/100 p-y by years 3–5.
The decrease in rates of TEAEs and the stable rates of SAEs, other malignancies and MACE during up to 5 years of ixekizumab dosing are consistent with previous reports describing a favorable safety profile of ixekizumab following shorter durations of exposure.
Eli Lilly and Company.
KeywordsAdverse events Etanercept IL-17 Integrated analysis Ixekizumab Safety Psoriasis
Key Summary Points
Psoriasis is a chronic disease that requires long-term management; thus, long-term data on the safety and tolerability of psoriasis treatments are essential to inform patient management decisions.
We examined the long-term safety and tolerability of ixekizumab based on dosing of up to 5 years in 13 clinical trials in patients with moderate-to-severe psoriasis.
The incidence rates of treatment-emergent adverse events, serious adverse events and adverse events of special interest were either stable or decreased with increasing duration of ixekizumab therapy.
These findings are consistent with previous reports on ixekizumab and indicate that no new safety findings have emerged following longer durations of dosing.
Moderate-to-severe psoriasis is a chronic immune-mediated inflammatory disease associated with substantial comorbidities [1, 2]. At present, psoriasis requires long-term management; thus, long-term data on the safety and tolerability of treatments are essential to inform patient management decisions. Ixekizumab is a high-affinity monoclonal antibody that selectively targets interleukin (IL)-17A  and is approved for the treatment of moderate-to-severe plaque psoriasis based on the efficacy and consistent safety profile shown in the UNCOVER program. IL-17 plays a role in host mucocutaneous defense, and therefore IL-17 inhibition is linked to adverse events (AEs) in patients with candidiasis [4, 5, 6, 7]. Furthermore, while the role of IL-17 in inflammatory bowel disease (IBD) and cardiovascular disease is unclear, IL-17 inhibitors are of special interest in treating these events [8, 9, 10, 11, 12, 13, 14]. Overall, the safety profile of ixekizumab has demonstrated comparability to biologic therapies with different mechanisms of action that are approved for plaque psoriasis, namely etanercept (UNCOVER-2 and -3 studies)  and ustekinumab (IXORA-S study) .
Two previous safety updates have addressed cumulative data from the ixekizumab development program. Strober et al. reported safety data from seven clinical trials (9 April 2015 data lock) . Langley et al. provided an update of safety data from 11 clinical trials (15 September 2016 data lock) . Here we report our results from an examination of the long-term safety and tolerability of ixekizumab based on 17,003.4 patient-years (p-y) of ixekizumab exposure from 13 clinical trials (20 September 2018 data lock) in patients with psoriasis.
The present analysis included the cumulative safety data covering up to 319 weeks of ixekizumab exposure integrated from 13 controlled and uncontrolled ixekizumab clinical studies on psoriasis, including three phase 3, randomized, double-blind, controlled pivotal clinical studies (UNCOVER-1, -2 and -3; Fig. 1) [15, 19]. All patients were ≥ 18 years of age with moderate-to-severe plaque psoriasis (≥ 10% body surface area [BSA] involvement, with the exception of the IXORA-Q study, in which the cutoff was ≥ 1% BSA involvement, as the study assessed genital psoriasis for which a lower threshold is considered) and had a Static Physician’s Global Assessment of ≥ 3 and a Psoriasis Area and Severity Index ≥ 12 at baseline (excepting those in IXORA-Q). The UNCOVER-1, -2 and -3 and IXORA-Q [15, 19, 20] studies had 12-week, randomized, placebo-controlled periods, with the UNCOVER-2 and -3 studies having an additional etanercept arm up to week 12. The IXORA-S study also had an ustekinumab treatment arm; however, the ustekinumab data are not analyzed herein due to limited patient numbers (N = 166) and duration of therapy (52 weeks) .
The AEs for the September 2018 update were classified based on the Medical Dictionary for Regulatory Activities version 21.0 (https://www.meddra.org/sites/default/files/guidance/file/whatsnew_21_0_english.pdf); data for the placebo-controlled period of UNCOVER-1, -2 and -3 were based on version 17.0 (https://www.meddra.org/sites/default/files/guidance/file/whatsnew_17_0_english.pdf). A treatment-emergent AE (TEAE) was an AE that first occurred or worsened in severity after baseline and within the treatment period. The lowest level terms have been used for the TEAE computation, and preferred terms are presented. Infections with an onset date ≤ 14 days before or after neutrophil count collection were considered temporally associated with the corresponding neutropenia count. Safety topics of special interest included injection site reactions (ISRs), serious infections, candidiasis, major adverse cardiovascular events (MACE), non-melanoma skin cancer (NMSC), malignancies (excluding NMSC) and IBD (including Crohn’s disease and ulcerative colitis). The IBD events were adjudicated using the Registre Epidemiologique des Maladies de l’Appareil Digestif (EPIMAD) criteria [21, 22]. MACE were adjudicated by an external adjudication committee for ten of the 13 studies (n = 5697).
Data are summarized overall from 13 clinical studies, and for the induction period (12 weeks) of three psoriasis clinical studies (UNCOVER-1, -2 and -3). All randomized patients who received ≥ 1 dose of the study drug were included in the safety analysis population. Frequencies or exposure-adjusted incidence rates (IRs) of AEs are summarized overall and for some events of interest by 1-year (365-day) intervals. The IRs are expressed as number of unique patients with a particular category of event per 100 p-y, using the entire duration of exposure during each interval. Multiple AEs that occurred in different intervals were counted multiple times.
As long-term control data were not available, previously published data for the placebo and ixekizumab groups from the large phase 3 UNCOVER studies are reported as time-adjusted IRs; baseline characteristics for the same patient groups are also presented.
Baseline characteristics for the overall patient population
Placebo (UNCOVER-1, -2 and -3)
Etanercept (UNCOVER-2 and -3)
Ixekizumab (UNCOVER-1, -2 and -3)
Age, mean (SD) years
Male, % (n/N)
Race, % (n/N)
Geographic region, % (n/N)
BMI, mean kg/m2 (SD)
Prior systemic therapy, % (n/N)
Biologic and nonbiologic
Prior biologic therapy, % (n/N)
Duration of psoriasis symptoms, mean years (SD) [median]
19.1 (12.1) [16.7]
18.5 (12.1) [16.4]
18.8 (12.2) [16.9]
18.7 (12.2) [16.7]
Tobacco use, yes, % (n/N)
Summary of the most commonly reported adverse events
Combined Ixe therapy period (N = 5898)
Placebo (N = 791)
Ixekizumab (N = 2328)
Etanercept (N = 739)
Mean follow-up (weeks)
Total follow-up (p-y)
Patients with ≥ 1 TEAE
Common TEAEs (preferred terms)
Nasopharygitis/viral upper resp. tract infection
Upper resp. tract infection
Injection site reaction
Urinary tract infection
AE leading to D/C
SAE by body system
Infections and infestations
Injury, poisoning and procedural complications
Neoplasms benign, malignant and unspecified (including cysts and polyps)
Musculoskeletal and connective tissue disorders
Nervous system disorders
Respiratory, thoracic, and mediastinal disorders
Renal and urinary disorders
Skin and subcutaneous tissue disorders
Metabolism and nutrition disorders
General disorders and administrative site conditions
Combined Periods of Ixekizumab Therapy
Incidence rates for TEAEs for the combined ixekizumab treatment period were compared with either placebo or ixekizumab treatment during the induction period. Exposure-adjusted IRs for any TEAE were lower in the combined ixekizumab treatment period (30.0/100 p-y) than in placebo-controlled period (placebo 205.5/100 p-y or ixekizumab 255.2/100 p-y; Table 2). The same was true for the most common TEAEs of nasopharyngitis/viral upper respiratory infection (8.9/100 p-y overall vs. 38.3/100 p-y for placebo or 40.2/100 p-y for ixekizumab through 12 weeks) upper respiratory tract infection (5.4/100 p-y overall vs. 15.6/100 p-y or 18.0/100 p-y); ISR (3.4/100 p-y vs. 5.0/100 p-y or 38.5/100 p-y) and headache (3.0/100 p-y vs. 12.8/100 p-y or 18.9/100 p-y), which were more common among ixekizumab-treated patients than placebo-treated patients during the induction phase. The rates of AEs leading to study discontinuation, any SAEs and SAEs by body system generally decreased or remained static when compared between the induction period and the combined ixekizumab treatment period (Table 2).
Summary of treatment-emergent adverse events of special interest during combined ixekizumab dosing
Injection site reactions
Serious infections and infestations
Other malignancies (excluding NMSC)
Inflammatory bowel disease (narrow terms)
Inflammatory bowel disease
MACE, adjudicated (n = 5697)
Myocardial infarction, nonfatal
Thirty-four deaths were reported, with 32 deaths occurring during ixekizumab treatment (IR during treatment 0.2/100 p-y; range 0.1–0.3 per 100 p-y by year). For all deaths, causes were cardiac-related (n = 14), malignancies (n = 4), unknown (n = 5), respiratory causes (n = 3), trauma/accident (n = 3), severe hemorrhagic cerebral infarction (n = 1), death concomitant with severe senile dementia (n = 1), ulcerative colitis (n = 1), cholecystolithiasis (n = 1) and septic shock (n = 1). MACE accounted for most deaths, and none of the deaths were considered related to the study drug.
Adverse Events of Special Interest
As assessed based on years of treatment, IRs were generally constant or decreasing for ISRs, allergic reactions/hypersensitivity, serious infections, candidiasis, MACE, NMSC, other malignancies and IBD across the treatment periods (Fig. 2).
Administration Site or Drug Reactions
As noted above, the IRs for ISRs, as well as for allergic reactions/hypersensitivity, decreased over time through the 5 years of the study. One or more ISRs were reported for 15.1% of patients (Table 3), with 10.0, 4.5 and 0.6% experiencing mild, moderate and severe reactions, respectively, at an overall IR of 5.2 per 100 p-y. The most commonly reported specific terms were ISR (IR 3.4/100 p-y), injection site erythema (1.1/100 p-y) and injection site pain (0.6/100 p-y). A total of 13 patients discontinued the study drug due to injection site–related TEAEs (0.1/100 p-y). The most frequently reported allergic events (IR ≥ 0.5) were contact dermatitis (IR 1.1/100 p-y), eczema (1.0/100 p-y), urticaria (0.6/100 p-y), dermatitis (0.5/100 p-y), allergic rhinitis (0.5/100 p-y) and rash (0.5/100 p-y). There was one case of worsening eczematous reaction that was considered a possible paradoxical reaction, but the patient recovered and continued in the study. Four SAEs of pustular psoriasis were reported. One event occurred after an upper respiratory tract infection; the patient recovered and continued in the clinical trial. Of three cases of pustular psoriasis events, two were considered related to the study drug by the investigator, and the third case was considered unrelated; all three patients discontinued the study drug. There were reports of potential anaphylaxis events; however, upon review, none occurred in temporal relationship to the administration of ixekizumab, and no confirmed cases of ixekizumab-related anaphylaxis have been identified in any clinical studies.
Combined ixekizumab (N = 5898)
Patients with ≥ 1 infection
Upper respiratory tract infection
Urinary tract infection
Patients with ≥ 1 serious infection/infestation
Latent tuberculosis was reported for 42 patients (IR 0.2/100 p-y), the mycobacterium complex test was positive for 43 patients (IR 0.2/100 p-y) and the tuberculin test was positive for 17 patients (IR 0.1/100 p-y); pulmonary tuberculosis or tuberculosis was determined for one patient (IR < 0.05/100 p-y) each. These findings were criteria for discontinuation for some of the studies and led to discontinuation in 20, 31, 13, 1 and 1 patients, respectively. There were no confirmed cases of tuberculosis reactivation; one de novo case of tuberculosis was reported in a country with a high tuberculosis burden.
Combined ixekizumab (N = 5898)
Non-melanoma skin cancer, n (%)
Basal cell carcinoma, n (%)
Squamous cell carcinoma, n (%)
Malignancies excluding NMSC, n (%)
Prostate cancer,bn (%)
Squamous cell carcinoma, n (%)
Invasive ductal breast carcinoma, n (%)
Colon cancer, n (%)
Lung cancer metastatic, n (%)
Candidiasis overall was reported by 327 patients (IR 1.9/100 p-y), with oral candidiasis reported by 140 patients (IR 0.8/100 p-y) (Table 3); one case of esophageal candidiasis led to study discontinuation; there were no reports of deep organ or bloodstream Candida infection.
Inflammatory Bowel Disease
Overall, TEAEs of IBD (narrow terms) were reported by a total of 26 patients (IR 0.2/100 p-y), largely as ulcerative colitis (n = 18; IR 0.1/100 p-y) and Crohn’s disease (n = 7, IR < 0.05/100 p-y; Table 3). Of the eight reports of Crohn’s disease from seven patients, four events occurred in the first year and two each were reported in the second and fifth years of treatment. As awareness of the role of IL-17 inhibition in IBD evolved after initiation of the psoriasis clinical trial program, a protocol amendment was instituted that allowed for post hoc adjudication of IBD in a retrospective manner. Per adjudication, prespecified specific and nonspecific terms for IBD were identified and evaluated as follows: 24 patients had reported IBD confirmed as ulcerative colitis (n = 16; IR 0.1/100 p-y) and Crohn’s disease (n = 8; IR < 0.05/100 p-y). As shown for unadjudicated cases (specific terms) in Fig. 3, the IR for adjudicated cases remained relatively constant over time (year 1, n = 14, IR 0.3/100 p-y; year 2, n = 6, IR 0.2/100 p-y; years 3 and 4, n = 1 each [each IR < 0.05/100 p-y]; year 5, n = 4, IR 0.2/100 p-y).
Major Adverse Cardiovascular Events
Major adverse cardiovascular events occurred in 84/5697 patients (IR 0.5/100 p-y) in studies with adjudication (total p-y 16,455.6) (Table 3). The most common category of events was nonfatal myocardial infarction (n = 45; IR 0.3/100 p-y), followed by vascular death (n = 20; IR 0.1/100 p-y) and nonfatal stroke (n = 20; IR 0.1/100 p-y).
Many factors must be considered when selecting the optimal therapy for psoriasis; important among these are the association of therapies with AEs, such as infection or malignancy, and the impact of therapy on comorbidities [23, 24]. We assessed safety events up to 5 years of therapy with ixekizumab in 5898 patients, for > 17,000 total p-y of exposure. IRs of TEAEs generally decreased or remained stable over time, and the overall rate of TEAEs was lower with longer duration of therapy compared to the first 12-week placebo-controlled period. Most AEs were not serious, and the rate of discontinuation due to AEs was low, with a decreasing trend over time. The overall rate of SAEs was stable across the study period, with no trend toward increasing rates of AEs with longer duration of exposure. This was also true for rates of malignancies, MACE and serious infections, which remained comparable to those for placebo or ixekizumab during the 12-week placebo-controlled induction period. These results support and confirm previous reports describing a favorable safety profile following shorter durations of ixekizumab exposure, and suggest that increased duration and total exposure to ixekizumab were not associated with additional or unexpected safety concerns [15, 17, 18].
Previous reports have noted infections as the most frequent AE associated with ixekizumab therapy. In the present report, infections were found to be generally mild to moderate in severity and seldom led to study discontinuation. The IR of severe infections (1.4/100 p-y) did not increase over time and was comparable to that reported in pooled safety data for up to 5 years of treatment with the anti-IL-12 and anti-IL-23 agent ustekinumab (1.1/100 p-y) , in pooled safety data primarily for 3 years for the tumor necrosis factor (TNF) inhibitor adalimumab (1.8/100 p-y)  and in data for up to 66 months in a single study of the Janus kinase inhibitor tofacitinib (1.2/100 p-y) . There were no reports of Grade 4 (< 0.5 × 109/L) neutropenia associated with infections; an infection temporally associated with Grade 3 (< 1.0–0.5 × 109/L) neutropenia was reported for three patients (0.1%; influenza [n = 1], otitis externa [n = 1] and nasopharyngitis [n = 1]) and infections associated with Grade 2 neutropenia (< 1.5–1.0 × 109/L) were reported for 27 (0.5%) patients. Consistent with the role of IL-17A in the suppression of mucocutaneous candidiasis, oral candidiasis was the most frequently reported opportunistic infection. Positive tuberculin tests led to discontinuation (which was protocol specified for a portion of the studies) for 66 patients. However, no cases of tuberculosis reactivation have been observed in the ixekizumab clinical development program, including in patients with latent or previously treated Mycobacterium tuberculosis infection. One case of de novo tuberculosis was reported in a country with a high tuberculosis burden. ISRs were also one of the most commonly reported AEs, and their IRs declined over time, as noted in a previous analysis that used most of the current dataset . Allergic reactions/hypersensitivities were more frequently reported during the first year, then stabilized or decreased moderately in subsequent years. The occurrence of potential paradoxical reactions, such as pustular psoriasis, were rare. SAEs classified as allergic reactions/hypersensitivity events and discontinuation of ixekizumab due to allergic reactions/hypersensitivities were uncommon, with 27 (0.5%) and 28 (0.5%) patients reporting such events, respectively. Overall, there was no indication of an increased risk for allergic reactions/hypersensitivity events with increasing durations of exposure to ixekizumab.
Findings regarding IBD in the present analysis were consistent with those of an earlier report on combined ixekizumab safety data collected over 3 years, indicating that Crohn’s disease and ulcerative colitis were uncommon . Annual IRs of patients with TEAEs (specific and broad terms) adjudicated (retrospective and prospective) per EPIMAD criteria as probable or definite Crohn’s disease and ulcerative colitis did not increase and remained stable for up to 5 years of therapy. As noted in a previous report on IBD in patients receiving ixekizumab, which assessed approximately two-thirds of the patients included herein over shorter periods of exposure, such rates are comparable to those reported in psoriasis cohort studies, but are difficult to compare directly to rates reported in studies of other biologics due to differences in criteria for reporting events .
Patients with psoriasis are at an increased risk of cardiovascular AEs, including a 10-year risk of MACE [29, 30, 31, 32, 33]. While a reduction in cardiovascular risk has been suggested for methotrexate or biologics in the treatment of rheumatoid arthritis [34, 35, 36], reports on cardiovascular risk reduction with psoriasis treatment have been contradictory [37, 38]. Low serum levels of IL-17 have been associated with a risk of repeat myocardial infarction; however, the role of IL-17 in atherosclerosis is complex, with conflicting results reported . In the present study, the overall incidence of MACE of 0.5/100 p-y was comparable to long-term results reported for patients receiving ustekinumab (0.44/100 p-y)  and adalimumab (0.36/100 p-y) , with no apparent increase in incidence with longer ixekizumab exposure. Determining whether biologics, including specific immunomodulators, are associated with increased, decreased or comparable rates of cardiovascular disease relative to rates in untreated patients with psoriasis or in patients receiving other psoriasis treatments will require further studies, such as observational studies or studies using claims database cohorts, and meta-analyses with large numbers of patients receiving various comparator treatments.
Patients with psoriasis may be at increased risk for some lymphoproliferative  and NMSC malignancies [41, 42], and there are concerns about the impact of long-term systemic treatment with anti-TNF therapies . The IR of malignancies other than NMSC (0.5/100 p-y) for up to 5 years of therapy with ixekizumab in this study was comparable to that for long-term ustekinumab (0.6/100 p-y)  and the anti-TNF therapies adalimumab (0.8/100 p-y)  and etanercept (estimated 0.55/100 p-y) . The IR of NMSC seen with ixekizumab of 0.3/100 p-y in this study was somewhat lower than that reported based on long-term safety data for ustekinumab (0.52/100 p-y)  or with adalimumab (0.6/100 p-y)  or etanercept (0.9 per 100 p-y)  in psoriasis. The ratio of basal cell carcinoma to squamous cell carcinoma expected in immunocompetent patients in the general population is 4:1, and is reversed in severely immunocompromised patients, such as transplant recipients ; thus, the ratio of 3.5:1 during long-term ixekizumab dosing was consistent with the expectation for immunocompetent patients. There were 34 total deaths reported over the 17,003.4 p-y of exposure to ixekizumab; the IR of 0.2/100 p-y is consistent with that reported for ustekinumab up to 5 years (0.22/100 p-y) . Most deaths in this study were secondary to cardiovascular disorders in patients with background risk factors.
The limitations of the present study include the following. First, although overall IRs of AEs decreased after the 12-week induction period, some of the decreases in AEs may be due to reporting fatigue and differences in recall due to increased time between visits at later time points. Secondly, the lack of a randomized placebo control group after the induction period limited our ability to directly compare IRs at later time points with a control population. Thirdly, the length of follow-up varied between studies, and the three largest studies, UNCOVER-1, -2 and -3, are not all completed; thus, it will be important to revisit these findings once all of the UNCOVER studies have been completed. Fourthly, certain adverse effects, such as MACE and malignancies, require longer observation periods and larger patient exposures to ascertain risk. Long-term safety studies, including post marketing studies, are ongoing to continue to evaluate the safety of ixekizumab; however, preliminary data up to 27 months from the Corrona observational database are consistent with the present results .
In conclusion, no new safety signals were identified with longer-term follow-up with ixekizumab, nor was any trend observed for an increase in IRs for any AE of special interest based on increased duration of therapy through 1–5 years. Thus, the long-term safety profile with ixekizumab up to 5 years was consistent with the favorable safety profile observed previously following shorter durations of ixekizumab exposure.
The studies described herein and the Rapid Service Fee were funded by Eli Lilly and Company.
Medical Writing Assistance
Thomas Melby (Syneos Health) assisted as a medical writer in the preparation of this manuscript, funded by Eli Lilly and Company.
All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article, take responsibility for the integrity of the work as a whole, and have given their approval for this version to be published.
April Armstrong has served as a research investigator and/or consultant to AbbVie, Janssen, Lilly, Leo, Novartis, UCB, Ortho Dermatologics, Dermira, Sanofi, Regeneron, BMS, Dermavant, and Modernizing Medicine. Carle Paul has served as consultant and/or investigator for AbbVie, Amgen, Boehringer, Celgene, Eli Lilly and Company, Janssen, Leo, Novartis, and Pfizer. Luis Puig has received: grants or research support or participated in clinical trials (paid to institution) from AbbVie, Almirall, Amgen, Boehringer Ingelheim, Janssen, Leo-Pharma, Eli Lilly and Company, Novartis, Pfizer, Regeneron, Roche, Sanofi, and UCB; honoraria or consultation fees (paid to self) from AbbVie, Almirall, Amgen, Baxalta, Biogen, Boehringer Ingelheim, Celgene, Gebro, Janssen, Leo-Pharma, Eli Lilly and Company, Merck-Serono, MSD, Mylan, Novartis, Pfizer, Regeneron, Roche, Sandoz, Samsung-Bioepis, Sanofi, and UCB; and has been a speaker for Celgene, Janssen, Eli Lilly and Company, MSD, Novartis, and Pfizer. Luis Puig is also a member of the journal’s Editorial Board. Wolf-Henning Boehncke has received honoraria as an advisor or speaker from the following companies: AbbVie, Almirall, Celgene, Janssen, Leo, Eli Lilly and Company, Novartis, Pfizer, and UCB. Michael Freeman has been a scientific adviser and/or investigator and/or speaker for Amgen, AbbVie, Allergan, Celgene, Dermira, Eli Lilly and Company, Galderma, Janssen, Leo Pharma, Novartis, Pfizer, Regeneron, Roche, and Sanofi/Genzyme. Hideshi Torii has received consulting fees or honoraria from the following companies: AbbVie, Eli Lilly and Company, Celgene, Janssen, Novartis, Kyowa Hakko Kirin, and Mitsubishi Tanabe Pharma. Kim Papp has been a consultant and/or scientific adviser and/or investigator and/or scientific officer and/or speaker for Amgen, Anacor, AbbVie, Akros, Allergan, Astellas, AstraZeneca, Baxalta, Baxter, BMS, Boehringer Ingelheim, Can-Fite, Celgene, Coherus, Dermira, Dow Pharma, Eli Lilly and Company, Forward Pharma, Galderma, Genentech, GSK, Janssen, Kyowa Hakko Kirin, Leo Pharma, Medimmune, Meiji Seika Pharma, Merck (MSD), Merck-Serono, Mitsubishi Pharma, Novartis, Pfizer, Regeneron, Roche, Sanofi/Genzyme, Takeda, UCB, and Valeant. Christopher E.M. Griffiths has received honoraria and/or research grant support (University of Manchester) from AbbVie, Almirall, Bristol Meyers Squibb, Celgene, Eli Lilly and Company, GSK, Janssen, LEO Foundation, Novartis, Pfizer, Sandoz, Sun Pharma, and UCB Pharma. Andrew Blauvelt has served as a scientific adviser and/or clinical study investigator for AbbVie, Aclaris, Akros, Allergan, Almirall, Amgen, Arena, Athenex, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Dermavant, Dermira Eli Lilly and Company, FLX Bio, Galderma, Genentech/Roche, GlaxoSmithKline, Janssen, Leo, Meiji, Merck Sharp & Dohme, Novartis, Pfizer, Purdue Pharma, Regeneron, Revance, Sandoz, Sanofi Genzyme, Sienna Pharmaceuticals, Sun Pharma, UCB Pharma, Valeant, and Vidac, and as a paid speaker for AbbVie, Regeneron, and Sanofi Genzyme. Kristian Reich has served as an advisor and/or paid speaker for and/or participated in clinical trials sponsored by AbbVie, Affibody, Amgen, Biogen, Boehringer Ingelheim Celgene, Centocor, Covagen, Forward Pharma, GlaxoSmithKline, Janssen-Cilag, Kyowa Kirin, Leo, Eli Lilly and Company, Medac, Merck Sharp & Dohme, Novartis, Ocean Pharma, Pfizer, Regeneron, Sanofi, Takeda, UCB Pharma, and Xenoport. Melinda Gooderham has been an investigator, speaker, advisory board member or consultant for AbbVie, Amgen, Akros, Arcutis, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Dermira, Dermavant, Eli Lilly and Company, Galderma, GSK, Janssen, Kyowa Kirin, LEO Pharma, Medimmune, Novartis, Pfizer, Regeneron, Roche, Sun Pharmaceuticals, UCB, and Valeant. Tadashi Terui has received research funds from Maruho Co. Ltd. and honoraria for speaker, consultancy and advisory board member from AbbVie, Boehringer Ingelheim, Celgene, Janssen, Kyowa Hakko Kirin Co., Ltd, Leo Pharma, Eli Lilly and Company, Mitsubishi Tanabe Pharma Corporation, Novartis, TAIHO Phamaceutical Co, and Sanofi. Mark G. Lebwohl is an employee of Mount Sinai Hospital, for which he receives research funds from: AbbVie, Amgen, AstraZeneca, Boehringer-Ingelheim, Celgene, Eli Lilly and Company, Incyte, Janssen/Johnson & Johnson, Kadmon, Leo Pharmaceuticals, Medimmune, Novartis, Pfizer, Sciderm, UCB, Ortho-dermatologics, and ViDac. Mark G. Lebwohl is also a consultant for Allergan, Almirall, Arcutis, Avotres, Birch biomed, Boehringer-Ingelheim, Bristol Myers Squibb, Cara, Castle Biosciences, Dermavant, Encore, Inozyme, LEO Pharma, Meiji, Menlo, Mitsubishi Pharma, Neuroderm LTD, Pfizer, Promius/Dr. Reddy, Theravance Biopharma, and Verrica. Mark G. Lebwohl is also a member of the journal’s Editorial Board. Lisa Renda is an employee and minor shareholder of Eli Lilly and Company. Noah Agada is an employee and minor shareholder of Eli Lilly and Company. Wen Xu is an employee and minor shareholder of Eli Lilly and Company. Gaia Gallo is an employee and minor shareholder of Eli Lilly and Company. Gaia Gallo is also a National Institute for Health Research (NIHR) Emeritus Senior Investigator and is funded in part by the NIHR Manchester Biomedical Research Centre.
Compliance with Ethics Guidelines
The protocols for all studies included in this analysis were approved by the Institutional Review Board or Ethics Committee at each participating site. All studies included in this analysis were conducted in accordance with the ethical principles of the Declaration of Helsinki. All eligible patients provided written informed consent before undergoing study-related procedures.
Eli Lilly and Company provides access to all individual participant data collected during the trial, after anonymization, with the exception of pharmacokinetic or genetic data. Data are available on request 6 months after the indication studied has been approved in the United States and European Union and after primary publication acceptance, whichever is later. No expiration date of data requests is currently set once data are made available. Access is provided after a proposal has been approved by an independent review committee identified for this purpose and after receipt of a signed data sharing agreement. Data and documents, including the study protocol, statistical analysis plan, clinical study report and blank or annotated case report forms, will be provided in a secure data sharing environment. For details on submitting a request, see the instructions provided at www.vivli.org.
This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
- 22.Reich K, Leonardi C, Langley RG, et al. Inflammatory bowel disease among patients with psoriasis treated with ixekizumab: a presentation of adjudicated data from an integrated database of 7 randomized controlled and uncontrolled trials. J Am Acad Dermatol. 2017;76(3):441–8.PubMedCrossRefGoogle Scholar
- 46.Grace E, Zhu B, Malley W, et al. Safety events occurring among patients exposed to ixekizumab in the Corrona Psoriasis Registry. Poster presented at: 6th Congress of the Skin Inflammation and Psoriasis International Network; 25–27 April 2019; Paris, France. J Eur Acad Dermatol Venereol 33[S3]:P001. https://doi.org/10.1111/jdv.15512.